Where does Leukocare AG rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Leukocare AG ranks #24,699 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Leukocare AG hold?

Leukocare AG holds 11 US utility patents granted between 2016 and 2025, spanning 13 technology areas.

What is Leukocare AG's Innovation Score?

Leukocare AG has an Innovation Score of 33.1 out of 100 (43rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Leukocare AG's patent grant rate increasing or decreasing?

Leukocare AG's recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Leukocare AG's patents?

Leukocare AG's patents average 15.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Leukocare AG patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Leukocare AG

Q: What technology areas does Leukocare AG focus on?

Leukocare AG's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 7 patents, ranking #1,382 of 4,144 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

USPTO PatentsView assignee record - 11 granted patents across 13 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Leukocare ranks #24,699 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 13 technology areas.

#24,699
of 49,997 US assignees by volume: 43rd percentile
by Innovation Score (33.1/100): 15.2
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24699 · Foreign Corporation #24,699 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,699/49,997
PHOTO-FINISH Lambda:4 Entwicklungen
CPC-FOCUS C12N · 13 areas
INNOV-THIN 33.1/100
CLAIMS-RICH 15.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lambda:4 Entwicklungen GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Leukocare’s 33.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (26%) Velocity 2.7 pts (8%) Breadth 12.7 pts (38%) Claim depth 9.1 pts (27%)

Qualcomm Incorporated · highest

85
Leukocare · this assignee

33
3D Lighting… · lowest

7

What this shows Leukocare's Innovation Score is 33.1/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Leukocare?

Each dot is one of Leukocare’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Leukocare’s own 15.2 claims/patent is at or below the 17.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Leukocare vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Leukocare's grants concentrate

Leukocare AG is a focused PatentsView assignee: 13 CPC subclasses with 63.6% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2016. By volume, Leukocare sits between Lambda:4 Entwicklungen GmbH and Licentia Group Limited.

Leukocare's three-year grant acceleration

Leukocare AG shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Lambda:4 Entwickl…

11
Laminated Film

11
Lehigh Defense

11
Lemi Technology

11
Libert Lift Solut…

11
Liberty Evans

11
Liberty Sport

11
Licentia Group

11
Leukocare ◀

11

What this shows Leukocare holds 11 patents at rank #24,704, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Leukocare

By rank, the assignees closest to #24,704 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Leukocare's primary technology class.

Leukocare's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 43rd percentile higher than 43% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Leukocare AG patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	9.1%
2017	1	9.1%
2018	1	9.1%
2019	2	18.2%
2020	1	9.1%
2021	2	18.2%
2022	1	9.1%
2023	1	9.1%
2025partial year	1	9.1%

Which technologies does Leukocare AG patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C07K - Peptides 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C12Y - Enzymes 2

G06N - Computing Arrangements Based ON Specific Computational Models 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

G16C - Computational CHEMISTRY; CHEMOINFORMATICS; Computational Materials Science 1

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

B01D - Separation 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Leukocare AG's patent record in context - here's where to go next.

Leukocare AG's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 63.6% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #24,699 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Leukocare AG against Lambda:4 Entwicklungen GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.